Matinas BioPharma Holdings, Inc. announced the appointment of Eric J. Ende, M.B.A, M.D., to its Board of Directors, effective April 3, 2017. Dr. Ende is a life sciences executive with over 20 years of financial leadership experience. Dr. Ende currently serves as President of Ende BioMedical Consulting Group. He also currently serves on the Technology Transfer Committee of Mount Sinai Innovation Partners. Previously, Dr. Ende consulted with Icahn Enterprises in connection with their efforts to appoint board members at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende will hold this position from April 3, 2017 until the next annual meeting of the company's shareholders or until his successor is elected and qualified, subject to his earlier resignation or removal.